
Opinion|Videos|September 6, 2024
Addressing Unmet Needs and Emerging Agents
Jonathan Silverberg, MD, PhD, MPH, evaluates persistent unmet needs in the field and highlights promising new treatments currently under development.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Despite the available treatment options, what are the remaining unmet needs or areas requiring further research and development in the management of disease states driven by type 2 inflammation?
- What emerging agents in the pipeline are you most excited for?
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
5 Novel FDA Approvals That Signal a Shift Toward Convenience-Driven Care
2
Rituximab Matches Ocrelizumab in Head-to-Head MS Trial
3
GLP-1 Plus Glucagon: The Mechanistic Case for Dual Receptor Agonism in Obesity and MASH
4
FDA Approves Gwyn Lo, a New Low-Dose Contraceptive Patch
5







